Entity Details

Primary name FA2H
Entity type gene
Source Source Link

Details

PrimaryID79152
RefseqGeneNG_017070
SymbolFA2H
Namefatty acid 2-hydroxylase
Chromosome16
Location16q23.1
TaxID9606
Statuslive
SourceGenomegenomic
SourceOriginnatural
CreationDate2001-02-24
ModificationDate2021-06-11

Ontological Relatives

UniProt IDsFA2H_HUMAN

GO terms

Show/Hide Table
GOName
GO:0001949 sebaceous gland cell differentiation
GO:0005506 iron ion binding
GO:0005783 endoplasmic reticulum
GO:0005789 endoplasmic reticulum membrane
GO:0006631 fatty acid metabolic process
GO:0006633 fatty acid biosynthetic process
GO:0006679 glucosylceramide biosynthetic process
GO:0006682 galactosylceramide biosynthetic process
GO:0016020 membrane
GO:0016021 integral component of membrane
GO:0020037 heme binding
GO:0030148 sphingolipid biosynthetic process
GO:0030258 lipid modification
GO:0032286 central nervous system myelin maintenance
GO:0032287 peripheral nervous system myelin maintenance
GO:0042127 regulation of cell population proliferation
GO:0042634 regulation of hair cycle
GO:0044857 plasma membrane raft organization
GO:0046513 ceramide biosynthetic process
GO:0061436 establishment of skin barrier
GO:0080132 fatty acid alpha-hydroxylase activity

Diseases

Show/Hide Table
Disease IDSourceNameDescription
612319 OMIMSpastic paraplegia 35, autosomal recessive (SPG35)A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG35 is a complicated form characterized by childhood onset of gait difficulties. It has a rapid progression and many patients become wheelchair-bound as young adults. Patients manifest cognitive decline associated with leukodystrophy. Other variable neurologic features, such as dystonia, optic atrophy, and seizures may also occur. The disease is caused by variants affecting the gene represented in this entry.

Interactions

35 interactions

InteractorPartnerSourcesPublicationsLink
FA2HMSR1BioGRID, IntAct32296183 details
FA2HDLG2BioGRID, IntAct32296183 details
FA2HERLIN1BioGRID, IntAct25416956 32296183 details
FA2HCREB3L1BioGRID, IntAct32296183 details
FA2HASGR2BioGRID, IntAct32296183 details
FA2HTLCD4BioGRID, IntAct32296183 details
FA2HSGPL1BioGRID, IntAct32296183 details
FA2HGPX8BioGRID, IntAct32296183 details
FA2HERGIC3BioGRID, IntAct32296183 details
FA2HGPR152BioGRID, IntAct32296183 details
FA2HEBPBioGRID, IntAct32296183 details
FA2HFAM209ABioGRID, IntAct32296183 details
FA2HELOVL4BioGRID, IntAct32296183 details
FA2HMARCHF8BioGRID, IntAct32296183 details
FA2HAQP6BioGRID, IntAct32296183 details
FA2HCD79ABioGRID, IntAct32296183 details
FA2HSLC10A6BioGRID, IntAct32296183 details
FA2HPGRMC2BioGRID, IntAct32296183 details
FA2HTMX2BioGRID, IntAct32296183 details
FA2HTMEM41ABioGRID, IntAct32296183 details
FA2HARMC12BioGRID, IntAct32296183 details
FA2HTMEM14BBioGRID, IntAct32296183 details
FA2HPEX12BioGRID, IntAct32296183 details
FA2HRIC3BioGRID, IntAct32296183 details
FA2HSYT2BioGRID, IntAct32296183 details
FA2HSLC10A1BioGRID, IntAct32296183 details
FA2HGPR37BioGRID, MINT28298427 details
FA2HCREB3BioGRID, IntAct21516116 31515488 details
FA2HDYNC1H1IntAct32814053 details
FA2HKLK6IntAct32814053 details
FA2HUBQLN4BioGRID, HPRD16713569 details
FA2HLMNABioGRID24623722 details
FA2HFCER1GBioGRID32296183 details
FA2HTCTN3BioGRID, IntAct26638075 details
FA2HH4C1BioGRID30804502 details